Equifax (EFX) Gets a Buy from Oppenheimer
In a report released yesterday, Owen Lau from Oppenheimer maintained a Buy rating on Equifax (EFX – Research Report), with a price target of $296.00. The company's shares closed yesterday at $263.41.
Confident Investing Starts Here:
Lau covers the Financial sector, focusing on stocks such as Coinbase Global, SEI Investments Company, and Cboe Global Markets. According to TipRanks, Lau has an average return of 11.0% and a 70.18% success rate on recommended stocks.
In addition to Oppenheimer, Equifax also received a Buy from Wells Fargo's Jason Haas CFA in a report issued on May 21. However, on May 13, Barclays maintained a Hold rating on Equifax (NYSE: EFX).
The company has a one-year high of $309.63 and a one-year low of $199.98. Currently, Equifax has an average volume of 1.11M.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why BioNTech Stock Soared Today
BioNTech and Bristol Myers Squibb are teaming up to develop a new cancer drug, BNT327. BioNTech has moved the drug into phase 3 trials, and now Bristol will help to fund further trials. Cash payments to BioNTech could exceed $11 billion over time. 10 stocks we like better than BioNTech Se › BioNTech (NASDAQ: BNTX), one of the companies made famous for its role developing vaccines with Pfizer (NYSE: PFE) during the COVID-19 pandemic, soared 20.2% through 12:50 p.m. Monday on news entirely unrelated to COVID. The German biotech announced this morning it is partnering with pharmaceuticals giant Bristol Myers Squibb (NYSE: BMY) to "co-develop and co-commercialize" BioNTech's drug candidate BNT327 as an immunotherapy against multiple kinds of cancer. BioNTech and Bristol will evenly split the costs of developing and commercializing BNT327, and will "work jointly to broaden and accelerate the development of this clinical candidate." The drug is already involved in "multiple" ongoing clinical trials, including an advanced phase 3 trial testing its usefulness in treating breast cancer and both small cell and non-small cell lung cancer. BioNTech CEO Dr. Uğur Şahin expressed the belief that "BNT327 has the potential to become a foundational immuno-oncology backbone, moving beyond single-mechanism checkpoint inhibitors and expanding into multiple solid-tumor indications." Bristol CEO Christopher Boerner agreed that BNT327 has "significant potential for transforming the standard of care for patients with solid tumors." There are more immediate benefits for BioNTech stock, beginning with Bristol Myers Squibb paying BioNTech $1.5 billion up front for the rights to team up and a further $2 billion in noncontingent payments through 2028 as drug development continues. Additional developmental, regulatory, and commercial milestones, which are contingent on successful development, could add a further $7.6 billion to BioNTech's balance sheet over time. With its lucrative COVID days behind it, BioNTech reported nearly $690 million in losses last year and turned free-cash-flow negative. A tidal wave of cash from Bristol Myers Squibb could really come in handy right about now. Before you buy stock in BioNTech Se, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and BioNTech Se wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb and Pfizer. The Motley Fool recommends BioNTech Se. The Motley Fool has a disclosure policy. Why BioNTech Stock Soared Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Why IonQ Stock Soared 47% in May
IonQ shares soared last month as the CEO compared it to Nvidia. The company also got a boost from its first-quarter earnings report and its acquisition of Lightsynq. Trading at a lofty price-to-sales ratio of over 100, the stock could easily fall from here. 10 stocks we like better than IonQ › Shares of IonQ (NYSE: IONQ), a developer of quantum computers and related platforms, were soaring last month, primarily in response to favorable coverage in Barron's, and an article that said it was aiming to be "the Nvidia of quantum computing." Additionally, the company reported first-quarter earnings that were generally in line with estimates and benefited from a broader risk-on sentiment in the market as worries about a trade war and a weakening economy faded. According to data from S&P Global Market Intelligence, the stock finished the month up 47%. As you can see from the chart, shares surged on the Barron's report on May 22, but then gave up some of those gains the following week as bullishness in the stock seemed to fade following an Nvidia's earnings report that did not highlight quantum computing. Quantum stocks generally rallied last month, as some investors bet that it could be the next big technology after artificial intelligence (AI), but IonQ, which is the most valuable of the group of quantum stocks, got a particular boost on May 22 thanks to the coverage in Barron's, as IonQ soared 37% that day. In an interview with Barron's, CEO Niccolo de Masi said, "We're in the business of quantum just like Nvidia and Broadcom are in the business of classical GPUs," adding, "I believe IonQ will be the Nvidia player. There will be other people that copy us and follow us; they have always copied and followed us." It was a bold statement coming from a company that earlier in May reported just $7.6 million in revenue in its first quarter, or less than 0.1% of what Nvidia and Broadcom reported. IonQ also continues to lose money as it invests in its technology. In the first quarter, the company reported a generally accepted accounting principles (GAAP) net loss of $32.3 million, and an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) loss of $35.8 million. Last month, the company also signed a memorandum of understanding (MOU) with Korea Institute of Science and Technology (KISTI), a technology research institute and supercomputing center. According to the MOU, the two companies will work together to collaborate in multiple areas to advance quantum computing. IonQ is now targeting revenue of $75 million-$95 million for the full year following its acquisition of Lightsynq, though justifying a market cap of $10 billion at that level of revenue seems difficult, especially when the company reported flat growth in the first quarter. Investors bullish on quantum computing might consider taking a small position in the stock, but it could easily plunge, considering it's been bid up on mostly hype. Before you buy stock in IonQ, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and IonQ wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Jeremy Bowman has positions in Broadcom and Nvidia. The Motley Fool has positions in and recommends Nvidia. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy. Why IonQ Stock Soared 47% in May was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
8 ways to remove old debt from your credit report
Unpaid debts and accounts in collections will stay on your credit report for seven years. Removing old debt from your credit report may help improve your score. You can file a dispute with the credit bureaus or enlist the help of a credit repair company to remove old debt and inaccuracies from your credit reports. Removing old debts from your credit report can help improve your credit score. Not every debt can be removed, and accurate items like late payments, discharges and debts in collections must remain for a certain amount of time. But removing those debts could be an important step in rebuilding your credit score. Combining multiple strategies may be most effective. Start by requesting free copies of your credit reports from the three major credit bureaus — Equifax, Experian and TransUnion — at to determine which credit reports have old debts on them. Each bureau records slightly different information, so old debt may appear on some reports and not others. Once you know what debt is on your credit report, verify the age of your debt and search your financial records to determine whether you paid off the account and, if so, whether you paid the original creditor or a debt collector. For delinquent debts, determine the date on which you first became delinquent. For example, if you missed your March 2022 payment and your bill eventually went into default, your delinquency date would be March 2022. No matter how many times a debt is sold (and resold), the date that counts for old debt is the date of delinquency with the original creditor. Information only stays on your credit report for a certain length of time. Unpaid debts, delinquent accounts and accounts in collections will remain on your credit report for seven years even if you eventually repaid them. Chapter 7 bankruptcies are visible for 10 years, and Chapter 13 bankruptcies, seven years. If your old debt is about to expire, the easiest approach is to wait for it to fall off. However, if the right number of years has passed and it's still showing, you can contact the appropriate credit bureau to have it removed. You may be able to get a collection account removed before the expiration if you have paid off the debt. Contact the collection agency and explain why you need the item removed. If there were circumstances beyond your control that led to delinquency, sharing those details may help convince the collection agency. It's up to the collection agency to decide whether they're willing to remove the account. Writing a clear, well-organized request and being in otherwise good credit standing can increase your chances. Occasionally, debts may show up on your credit report past their expiration by mistake. If this happens, you can file a dispute by contacting each credit bureau that is still reporting the old debt. The credit bureaus can be contacted by phone, mail, or online. Gather supporting documents such as receipts, letters and statements from your creditor. These documents will help the bureau verify when your account became delinquent. From there, they will open an investigation and contact your creditors to resolve the error. The Fair Credit Reporting Act requires credit bureaus to correct or delete any information that can't be verified or that is incorrect or incomplete, typically within 30 days. If the creditor can't verify the debt, it has to come off your report. Debt statute of limitations Debt collectors can still pursue unpaid debts even if they have been removed from your credit report. Agreeing to repay the debt could restart the statute of limitations on your debt. In addition to contacting the credit bureaus, consider contacting the creditor that is reporting the debt. In some cases, going directly through the creditor may be faster than going through the credit bureaus. As with the credit bureaus, state your case and include copies of any relevant documentation. Your creditor will have 30 days to investigate and respond to your claims. If you go this route, be careful to avoid making statements that could restart the debt clock if the statute of limitations has not expired. Hiring a credit repair company is another option for removing old or incorrect information from your credit report. For a fee, a credit repair company will identify errors on your reports, file disputes and even write goodwill letters on your behalf. This service can cost between $50 and $200 per month, so it's important to do your research and ensure you're using a reputable credit repair company. If you've contacted the credit bureaus and your creditor but the debt is still showing on your credit report, you can try complaining to someone higher up in the company reporting the debt. 'Direct your next letter to the president's attention at the company's headquarters address,' says Sonya Smith-Valentine, former managing attorney at Valentine Legal Group, 'because you get a different kind of response from the office of the president than you do from customer service.' You can also file a complaint with the Consumer Financial Protection Bureau. The CFPB forwards complaints to companies and publishes them in its public database, which can help you get a response. Note: As of February 2025, the Trump administration has halted the work of the CFPB. If you are unable to file a complaint with the CFPB, you can also file a complaint with your state attorney general. Dealing with debt collectors Debt collectors can pursue you after the statute of limitations has expired on your debt, but that doesn't mean you have to pay them. If you have exhausted other options for removing old debt from your credit report, then contacting an attorney may be the next step. Often, a letter on legal stationery is enough to move a company to address your concerns. However, if it is not, a lawyer can advise you on whether a lawsuit is a good option for your situation. If you do talk to an attorney, choose one who specializes in consumer rights, Smith-Valentine says. 'When you're dealing with the Fair Credit Reporting Act, it is very convoluted and you need someone who's done it, who understands it and who knows where the holes are.' One source for help is the National Association of Consumer Advocates, an organization of lawyers who specialize in credit and debt law. When you work hard to repair your credit, you want your credit report to reflect that. In some cases, you may be able to remove old debts that are still showing if they are old enough or fully repaid. You can reach out to the credit bureaus and your creditors yourself, or you can hire a credit repair company to handle the process for you.
